To explore the preoperative predictive efficacy of multimodal ultrasound based on microflow imaging(MFI) in Glypican-3(GPC-3) in hepatocellular carcinoma(HCC).
Methods
The general data and ultrasonographic data of patients with HCC confirmed by histopathology and hepatectomy from January 2019 to June 2023 were analyzed retrospectively. According to the gold standard of postoperative pathology, the patients were divided into GPC-3 positive group and GPC-3 negative group. Through analyze the correlation between multimodal ultrasound features and GPC-3, to determine the independent predictors of GPC-3, and to further analyze the preoperative predictive efficiency of Two-dimensional ultrasound(2D-US), contrast-enhanced ultrasound(CEUS) and microflow imaging(MFI) for GPC-3 of HCC.
Results
A total of 102 patients were enrolled in this study, including 60 GPC-3 positive patients(58.8%) and 42 GPC-3 negative patients(41.2%). Through univariate and multivariate analysis, it was found that there were significant differences in diameter(95%CI: 1.080–7.741, P = 0.034), start washout time(95%CI: 0.105–0.694, P = 0.007) and CEUS-MFI(95%CI: 1.180–4.553, P = 0.015) between the two groups, which were independent predictors of GPC-3 positive occurrence. The prediction efficiency of multimodal ultrasound combined with GPC-3 for HCC is better than that of single mode(P<0.05).
Conclusion
The feasibility of multimodal ultrasound in predicting GPC-3 of HCC before operation is confirmed.
JianZHuichuanSZhengW, et al.Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer2023; 12: 405–444.
2.
JieHWanqingCHongbingS, et al.China Guideline for liver cancer creening(2022,Beijing). J Clin Hepatol2022; 38: 1739–1758.
3.
LiYXLvWLQuMM, et al.Research progresses of imaging studies on preoperative prediction of microvascular invasion of hepatocellular carcinoma. Clin Hemorheol Microcirc2024; 88: 171–180.
4.
JungEMKaiserUHerrW, et al.Novel high-resolution contrast agent ultrasound techniques HiFR CEUS and SR CEUS in combination with shear wave elastography, fat assessment and viscosity of liver parenchymal changes and tumors. Clin Hemorheol Microcirc2024; 86: 263–273.
5.
Meitner-SchellhaasBJesperDGoertzRS, et al.Washout appearance of hepatocellular carcinomas using standardized contrast-enhanced ultrasound (CEUS) including an extended late phase observation - real-world data from the prospective multicentre DEGUM study. Clin Hemorheol Microcirc2023; 84: 413–424.
6.
WangKZhuYBaoJ, et al.Clinical application of preoperative shear wave dispersion for prediction of post liver failure in patients with hepatocellular carcinoma after hepatectomy. Clin Hemorheol Microcirc. 2023; 85: 223–234.
7.
SavsaniETantawiMCorinneE, et al.Contrast-enhanced ultrasound assessment of treatment response in a patient with multifocal hepatocellular carcinoma treated with transarterial chemo and radioembolization. Adv Ultrasound Diagn Ther2021; 5: 254–257.
8.
WuTSongZHuangH, et al.Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for HCC. Int Immunopharmacol2022; 113: 109393.
9.
WuYLiuHDingH. GPC-3 in HCC: current perspectives. J Hepatocell Carcinoma2024; 3: 63–67.
10.
WangLYaoMPanLH, et al.Glypican-3 is a biomarker and a therapeutic target of HCC. Hepatobiliary Pancreat Dis Int2015; 14: 361–366.
11.
LiNDongTWangP, et al.Predicting glypican-3 expression in hepatocellular carcinoma: a comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors. Clin Hemorheol Microcirc2023; 85: 407–420.
12.
LiuPLiWQiuG, et al.Multiparametric MRI combined with clinical factors to predict glypican-3 expression of HCC. Front Oncol2023; 13: 1142916.
13.
ChenYQinYWuY, et al.Preoperative prediction of glypican-3 positive expression in solitary HCC on gadoxetate-disodium enhanced magnetic resonance imaging. Front Immunol2022; 13: 973153.
14.
WangXLiLWangL, et al.The expression of ki-67 and glypican −3 in HCC was evaluated by comparing DWI and 18F-FDG PET/CT. Front Oncol2023; 13: 1026245.
15.
HeMXuLJiangT. Time-intensity curve analysis of hepatocellular carcinoma using two contrast-enhanced ultrasound methods: contrast pulse sequencing and contrast harmonic imaging. Adv Ultrasound Diagn Ther2020; 4: 217–222.
16.
LiNDongTWangP, et al.Predicting glypican-3 expression in HCC: a comprehensive analysis using combined CEUS and clinical factors. Clin Hemorheol Microcirc2023; 85: 407–420.
17.
DietrichCFNolsøeCPBarrRG, et al.Guidelines and good clinical practice recommendations for CEUS (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol2020; 46: 2579–2604.
18.
HanHDingHJiZ, et al.Primary application of micro-flow imaging technology in the diagnosis of hepatic tumors. Ultrasound Med Biol2019; 45: 395–401.
19.
DingZLiuWHeN, et al.Value of ultrasound elastography combined with CEUS and micro-flow imaging in differential diagnosis of benign and malignant breast lesions. Am J Transl Res2022; 13: 13941–13949.
20.
Sudoł-SzopińskaIHerregodsNDoriaAS, et al.Advances in musculoskeletal imaging in juvenile idiopathic arthritis. Biomedicines2022; 10: 2417.
21.
FontaineLGuidolinBViguierA, et al.Ultrasound characteristics of carotid web. J Neuroimaging2022; 32: 894–901.
22.
MaoYMuJZhaoJ, et al.The comparative study of color Doppler flow imaging, superb microvascular imaging, CEUS micro flow imaging in blood flow analysis of solid renal mass. Cancer Imaging2022; 22: 21.
23.
DongYZuoDQiuYJ, et al.Preoperative prediction of microvascular invasion (MVI) in HCC380 based on kupffer phase radiomics features of sonazoid CEUS (SCEUS): a prospective study. Clin Hemorheol Microcirc2022; 81: 97–107.
24.
ZhangYTLiPPChenXJ, et al.The predictive value of preoperative ki-67 combined with multimodal ultrasonography in microvascular invasion of primary liver cancer. Chin J Ultrasound Med2022; 38: 1248–1251.
25.
AdlerDDCarsonPLRubinJM, et al.Doppler Ultrasound color flow imaging in the study of breast cancer: preliminary findings. Ultrasound Med Biol1990; 16: 553–559.
26.
LiBLiuHShangHW, et al.Diagnostic value of glypican-3 in alpha fetoprotein negative HCC patients. Afr Health Sci2013; 13: 703–709.
27.
ZouZQDingYPLongB, et al.Gpc-3 is a notable diagnostic, prognostic and a latent targeted therapy marker in HCC. Hepatogastroenterology2010; 57: 1285–1290.
28.
FuSJQiCYXiaoWK, et al.Glypican-3 is a potential prognostic biomarker for HCC after curative resection. Surgery2013; 154: 536–544.
29.
YoritaKTakahashiNTakaiH, et al.Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in HCC. Liver Int2011; 31: 120–131.
30.
ShirakawaHSuzukiHShimomuraM, et al.Glypican-3 expression is correlated with poor prognosis in HCC. Cancer Sci2009; 100: 1403–1407.
31.
ZhouFShangWYuX, et al.Glypican-3: a promising biomarker for HCC diagnosis and treatment. Med Res Rev2018; 38: 741–767.
32.
XiaoWKQiCYChenD, et al.Prog-nostic significance of glypican-3 in HCC: a meta-analysis. BMC Cancer2014; 14: 104.
33.
WuJPDingWZWangYL, et al.Radiomics analysis of ultrasound to predict recurrence of HCC after microwave ablation. Int J Hyperthermia2022; 39: 595–604.
34.
ZhouYDingJQinZ, et al.Predicting the survival rate of patients with HCC after thermal ablation by nomograms. Ann Transl Med2020; 8: 1159.
35.
WangHFengLHQianYW, et al.Does microvascular invasion in Barcelona clinic liver cancer stage A multinodular HCC indicate early-stage behavior?Ann Transl Med2019; 7: 428.
36.
WangXLiLWangL, et al.The expression of ki-67 and glypican −3 in HCC was evaluated by comparing DWI and 18F-FDG PET/CT. Front Oncol2023; 13: 1026245.
37.
ZhaoJGaoSSunW, et al.Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive HCC. Eur J Radiol2021; 139: 109732.
38.
WellingTHEddingerKCarrierK, et al.Multicenter study of staging and therapeutic predictors of HCC recurrence following transplantation. Liver Transpl2018; 24: 1233–1242.
39.
ChenYQinYWuY, et al.Preoperative prediction of glypican-3 positive expression in solitary HCC on gadoxetate-disodium enhanced magnetic resonance imaging. Front Immunol2022; 13: 973153.
40.
LiNDongTWangP, et al.Predicting glypican-3 expression in HCC: a comprehensive analysis using combined CEUS and clinical factors. Clin Hemorheol Microcirc2023; 85: 407–420.
41.
HeYLiuFMouS, et al.Prognostic analysis of HCC on the background of liver cirrhosis via CEUS and pathology. Oncol Lett2018; 15: 3746–3752.
42.
JungEMPleyerLDropcoI, et al.Dynamic contrast ultrasound diagnostics (CEUS) of liver lesions and post-treatment control with A new high-resolution examination technique (HiFR) and perfusion. J Gastrointestin Liver Dis2024; 33: 362–371.
43.
SiqiCJuanCYunlinH, et al.Analysis of sonazoid enhaneed contrast enhanced ultrasound features of hepatocellular carcinomas with different tnmor sizes. Chin J Ultrasound Med2024; 40: 1357–1360.
44.
FanPLDingHMaoF, et al.Enhancement patterns of small HCC (≤ 30 mm) on CEUS: correlation with clinicopathologic characteristics. Eur J Radiol2020; 132: 109341.
45.
HuangJYLiJWLuQ, et al.Diagnostic accuracy of CEUS LI-RADS for the characterization of liver nodules 20 mm or smaller in patients at risk for HCC. Radiology2020; 294: 329–339.
46.
RanQHuYFYouYF. Analysis of the relationship between CEUS findings and histopathology, differentiation and prognosis of HCC under the background of liver cirrhosis. Anhui Med Pharm J2021; 25: 681–685.
47.
HanHDingHJiZ, et al.Primary application of micro-flow imaging technology in the diagnosis of hepatic tumors. Ultrasound Med Biol2019; 45: 395–401.
48.
KuangXFWangHYXiangJJ, et al.Application of constrast-enhanced ultrasound-micro flow imaging technique in differential diagnosis of benign and malignant renal tumors. Chin J Ultrasonogr2022; 31: 665–670.
